Overview
Wegovy label: BMI ≥30, or BMI ≥27 with weight-related comorbidity. 2024 expansion: adults with overweight/obesity + established CVD (no BMI floor for CV indication).
Related guides
- 503A vs 503B Compounding Pharmacies Explained
- Semaglutide Cost Guide — Brand vs Compounded Pricing
- Semaglutide Side Effects — What Patients Report
- Semaglutide Dosing Schedule
- Compounded vs Brand-Name Semaglutide
- Semaglutide Insurance Coverage
- How Semaglutide Works — Mechanism Explained
- Semaglutide and Cardiovascular Health